MaxCyte signs licensing deal with Myeloid Therapeutics
pharmafile | January 11, 2021 | News story | Sales and Marketing | MaxCyte, Myeloid Therapeutics
MaxCyte, a global cell-based therapies and life sciences company, and Myeloid Therapeutics, a company harnessing and reprogramming myeloid cells to treat cancers, have announced the signing of a clinical and commercial licensing agreement.
Myeloid Therapeutics will obtain non-exclusive clinical and commercial rights to use MaxCyte’s Flow Electroporation technology and ExPERT platform, enabling Myeloid to advance its pipeline programs, including for engineered cell therapies targeting solid tumors, T cell lymphoma, and glioblastoma.
In return, MaxCyte is entitled to receive undisclosed development and approval milestone and sales-based payments, along with other licensing fees.
Daniel Getts, CEO of Myeloid, said: “We are very excited to be working with MaxCyte, an established leader in cell engineering. This agreement provides long-term access to MaxCyte’s unique electroporation technology platform, representing an important enabling step in the continued clinical advancement of targeted cell-based therapies, for patients with few if no options.
“The ease of use and integration of MaxCyte instruments into our workflow allows us to envision rapid-same-day turnaround of cell treatments for patients presenting with aggressive tumors.”
Doug Doerfler, President and CEO of MaxCyte, also commented: “We are proud to support Myeloid’s work and are excited about the company’s novel approach to engineering and harnessing the innate capabilities of the myeloid cell.
“This agreement represents an important achievement for MaxCyte as it expands the use of our next-generation technology platform to support engineering in novel cell types. Myeloid’s ATAK technology is being developed for several critical applications in cancer.”
Darcy Jimenez
